Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE

64 ICER Thresholds KCE Reports 100
50. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis)
application of economics to real world problems. J Health Econ. 1993;12(4):469-76.
51. van Hout BA, Al MJ, Gordon GS, Rutten F. Costs, effects and C/E-ratios alongside a clinical
trial. Health Econ. 1994;3(5):309-19.
52. Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on
generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235-51.
53. World Health Organization. Making Choices in Health: WHO guide to cost-effectiveness
analysis. Geneva: WHO; 2003.
54. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ.
1997;16(1):1-31.
55. Weinstein MC, editor. From cost-effectiveness ratios to resource allocation: where to draw
the line? Cambridge: Cambridge University Press; 1995.
56. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it
increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637-41.
57. Birch S, Donaldson C. Valuing the benefits and costs of health care programmes: where's the
'extra' in extra-welfarism? Soc Sci Med. 2003;56(5):1121-33.
58. Dickson M, Hurst J, Jacobzone S. Survey of Pharmacoeconomic Assessment Activity in Eleven
Countries. Paris: Directorate for Employment, Labour and Social Affairs; 2003. OECD Health
Working Papers 4 (4) Available from: http://www.oecd.org/dataoecd/27/25/2955828.pdf
59. van der Zee J, Kroneman MW. Bismarck or Beveridge: a beauty contest between dinosaurs.
BMC Health Serv Res.7:94.
60. Lameire N, Joffe P, Wiedemann M. Healthcare systems--an international review: an overview.
Nephrol Dial Transplant.14 Suppl 6:3-9.
61. Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, et al. Searching for a
threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.
J Health Serv Res Policy. 2007;12(1):56-8.
62. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the
cost-effectiveness threshold. J Health Serv Res Policy. 2006;11(1):46-51.
63. Gafni A. Economic Evaluation of Health Care Interventions: The biggest bang for the buck or
the bigger bucks for the bang? In.
64. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc
Sci Med. 2006;62(9):2091-100.
65. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors
influence its decisions? A binary choice analysis. Health Econ. 2004;13(5):437-52.
66. Appleby J, Devlin N, Parkin D. NICE's cost effectiveness threshold. BMJ. 2007;335(7616):358-9.
67. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ.
2004;329(7459):224-7.
68. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where
we want to be? J Health Econ. 1992;11(3):279-96.
69. Karlsson G, Johannesson M. Cost-effectiveness analysis and capital costs. Soc Sci Med.
1998;46(9):1183-91.
70. Stinnett AA, Paltiel AD. Mathematical programming for the efficient allocation of health care
resources. J Health Econ. 1996;15(5):641-53.
71. Thiry N, Lambert ML, Cleemput I, Huybrechts M, Neyt M, Hulstaert F, et al. HPV Vaccination
for the Prevention of Cervical Cancer in Belgium: Health Technology Assessment. In: KCE
Reports. Brussels: Belgian Health Care Knowledge Centre (KCE); 2007.
72. Claxton K. Oft, Vbp: Qed? Health Econ. 2007;16(6):545-58.
73. Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. J Health Econ.
2008;27(5):1224-36.
74. Ethical aspects of cost-utility analysis. In: 4th Forum of National Ethics Councils in EU
Countries. Amsterdam; 2004.
75. Bleichrodt H, Diecidue E, Quiggin J. Equity weights in the allocation of health care: the rankdependent
QALY model. J Health Econ. 2004;23(1):157-71.